Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Equity Average (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Equity Average for 7 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 46.13% to $1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 46.13% increase, with the full-year FY2025 number at $1.2 billion, up 96.27% from a year prior.
  • Equity Average was $1.3 billion for Q4 2025 at Kymera Therapeutics, up from $958.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.3 billion in Q4 2025 to a low of $266.7 million in Q2 2021.
  • A 5-year average of $587.7 million and a median of $473.7 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 432.4% in 2021, then decreased 21.19% in 2023.
  • Kymera Therapeutics' Equity Average stood at $471.4 million in 2021, then increased by 6.39% to $501.5 million in 2022, then dropped by 21.19% to $395.3 million in 2023, then soared by 118.66% to $864.3 million in 2024, then skyrocketed by 46.13% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Equity Average are $1.3 billion (Q4 2025), $958.9 million (Q3 2025), and $878.9 million (Q2 2025).